A cost-effectiveness clinical decision analysis model for schizophrenia

American Journal of Managed Care

Volumn 4, Issue 3, 1998, Pages 345-355

  Palmer, Cynthia S ^a   Revicki, Dennis A ^a   Genduso, Laura A ^b   Hamilton, Susan H ^b   Brown, Ruth E ^a  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ARTICLE; CONSERVATIVE TREATMENT; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DISABILITY; DRUG COST; HOSPITALIZATION; MEDICAL CARE; MEDICAL DECISION MAKING; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; RELAPSE; SCHIZOPHRENIA; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; COST-BENEFIT ANALYSIS; DECISION SUPPORT SYSTEMS, CLINICAL; HALOPERIDOL; HUMANS; MARKOV CHAINS; PIRENZEPINE; QUALITY-ADJUSTED LIFE YEARS; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME; UNITED STATES;

EID: 0031874126     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Lehman AF, Thompson JW, Dixon LB, et al. Schizophrenia: Treatment outcomes research. Schizophr Bull 1995; 21:561-566.
2. Eisenberg JM. Clinical economics: A guide to the economic analysis of clinical practices. JAMA 1989;262:2879-2886.
3. Hargreaves WA, Shumway M. Pharmacoeconomics of antipsychotic drug therapy. J Clin Psychiatry 1996;57(suppl 9):66-76.
4. Revicki DA, Luce BR. Methods of pharmacoeconomic evaluation of new medical treatments in psychiatry. Psychopharmacol Bull 1995;31:57-65.
5. Dixon LB, Lehman AF, Levine J. Conventional antipsychotic medications for schizophrenia. Schizophr Bull 1995;21:567-578.
6. Kane JM. Clinical psychopharmacology of schizophrenia. In: Gabbard GO, ed. Treatment for Psychiatric Disorders. Washington, DC: American Psychiatric Press; 1995.
7. Weiden PJ, Dixon L, Frances A, et al. Neuroleptic noncompliance in schizophrenia. In: Tamminga CA, Sculz SC, eds. Advances in Neuropsychiatry and Psychopharmacology: Schizophrenia Research. Vol 1. New York, NY: Raven Press; 1991.
8. Casey DE. Motor and mental aspects of extrapyramidal syndromes. Int Clin Pyschopharmacol 1995;10 (suppl 3):105-114.
9. Tollefson GD, Beasley CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia, schizoaffective and schizophreniform disorders: Results of an international collaborative trial. Am J Psychiatry 1997; 154:457-465.
10. Beasley CM, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-123.
11. Beasley C, Tran P, Beuzen JN, et al. Long-term continuation therapy with the novel antipsychotic olanzapine: A review of the clinical experience. Presented at the Collegium Internationale Neuro Psychopharmacologicum; June 23-27, 1996; Melbourne, Australia.
12. Revicki DA, Genduso L, Hamilton S, et al. Quality of life outcomes for olanzapine and haloperidol treatment for schizophrenia and related psychotic disorders. Presented at the 149th annual meeting of the American Psychiatric Association; May 1996; New York, NY.
13. Pauker SG, Kassirer JP. Medical progress - decision analysis. N Engl J Med 1987;316:250-258.
14. Weinstein MC, Fineberg HV. Clinical Decision Analysis. Philadelphia, PA: WB Saunders Co; 1980.
15. Sonnenberg FA, Roberts MS, Tsevat J, et al. Toward a peer review process for medical decision analysis models. Med Care 1994;32:JS52-JS64.
16. Drummond MF, Stoddart G, Torrance GW. Methods for the Evaluation of Health Care Programmes. Oxford, England: Oxford University Press; 1987:1.15.
17. Bennett KJ, Torrance GW. Measuring health state preferences and utilities:. Rating scale, time trade-off and standard gamble techniques. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. New York, NY: Lippincott-Raven; 1996:253-266.
18. Torrance GW. Designing and conducting cost-utility analyses. In Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. New York, NY: Lippincott-Raven; 1996:1105-1112.
19. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-418.
20. Cohen LJ, Test MA, Brown RL. Suicide and schizophrenia: Data from a prospective community treatment study. Am J Psychiatry 1990;147:602-607.
21. Gilbert PL, Harris MJ, McAdams LA, et al. Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry 1995;52:173-178.
22. Johnson DAW. Drug treatment of schizophrenia. In: Bebbington P, McGuffin P, eds. Schizophrenia: The Major Issues. Oxford, England: The Medical Health Foundation and Heinemann Medical Books; 1988:158-171.
23. Baldessari RJ, Viguera AC. Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry 1995;52: 189-192.
24. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale Manual. North Tonawanda, NY: Multi-Health Systems; 1986.
25. Davies LM, Drummond MF. Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. Br J Psychiatry 1993;162:38-42.
26. Revicki DA, Shakespeare A, Kind P. Preferences for schizophrenia-related health states: A comparison of patients, caregivers and psychiatrists. Int Clin Psychopharmacol 1996;11:101-108.
27. US Bureau of Labor Statistics. CPI Detailed Report. Washington, DC: Department of Labor; December 1995:71.
28. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995;21:419-429.
29. Palmer CS, Revicki DA, Halpern MT, et al. The cost of suicide and suicide attempts in the United States. Clin Neuropharmacol 1995;18(suppl 3):S25-S33.
30. x. 5th ed. Riverside, CT: Denniston Publishing Inc; 1995:496-498, 957-960, 1726-1730.
31. Glazer WM, Ereshefsy L. A pharmacoeconomic model of outpatient neuroleptic therapy in "revolving door" schizophrenic patients. J Clin Psychiatry 1996;57:337-345.
32. Health Care Financing Administration. Payment for part B medical and other health services. Fed Regist 1994(Dec 8);59:235.
33. Ridgewood Financial Institute. Fee, practice and managed care survey. Psychotherapy Finances 1995;21(249): 1-8.
34. National Association of Psychiatric Health Systems. Trends in Psychiatric Health Systems: 1995 Annual Survey, Final Report. Washington, DC: National Association of Psychiatric Health Systems; 1995:13.
35. Umbricht D, Kane JM. Risperidone: Efficacy and safety Schizophr Bull 1995;21:593-606.
36. Report of the Task Force on Principles for Economic Analysis of Health Care Technology. Ann Intern Med 1995;123:61-70.
37. International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals. JAMA 1993;269:2282-2286.